You are here

Nat Genet DOI:10.1038/ng.3588

Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax.

Publication TypeJournal Article
Year of Publication2016
AuthorsHupalo, DN, Luo, Z, Melnikov, A, Sutton, PL, Rogov, P, Escalante, A, Vallejo, AF, Herrera, S, Arevalo-Herrera, M, Fan, Q, Wang, Y, Cui, L, Lucas, CM, Durand, S, Sanchez, JF, G Baldeviano, C, Lescano, AG, Laman, M, Barnadas, C, Barry, A, Mueller, I, Kazura, JW, Eapen, A, Kanagaraj, D, Valecha, N, Ferreira, MU, Roobsoong, W, Nguitragool, W, Sattabonkot, J, Gamboa, D, Kosek, M, Vinetz, JM, González-Cerón, L, Birren, BW, Neafsey, DE, Carlton, JM
JournalNat Genet
Date Published2016 Aug
KeywordsAntimalarials, Drug Resistance, Genetic Markers, Humans, Malaria, Vivax, Metagenomics, Plasmodium vivax, Selection, Genetic, Transcriptome

Plasmodium vivax is a major public health burden, responsible for the majority of malaria infections outside Africa. We explored the impact of demographic history and selective pressures on the P. vivax genome by sequencing 182 clinical isolates sampled from 11 countries across the globe, using hybrid selection to overcome human DNA contamination. We confirmed previous reports of high genomic diversity in P. vivax relative to the more virulent Plasmodium falciparum species; regional populations of P. vivax exhibited greater diversity than the global P. falciparum population, indicating a large and/or stable population. Signals of natural selection suggest that P. vivax is evolving in response to antimalarial drugs and is adapting to regional differences in the human host and the mosquito vector. These findings underline the variable epidemiology of this parasite species and highlight the breadth of approaches that may be required to eliminate P. vivax globally.


Alternate JournalNat. Genet.
PubMed ID27348298
PubMed Central IDPMC5347536
Grant ListD43 TW007393 / TW / FIC NIH HHS / United States
U19 AI089702 / AI / NIAID NIH HHS / United States